Drug General Information
Drug ID
Former ID
Drug Name
Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx
Drug Type
Indication Autoimmune diabetes [ICD10:E08-E13] Phase 2 [524991], [543089]
Ablynx NV
Target and Pathway
Target(s) Interleukin-6 receptor Target Info [533248]
KEGG Pathway Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
PI3K-Akt signaling pathway
Jak-STAT signaling pathway
Hematopoietic cell lineage
Non-alcoholic fatty liver disease (NAFLD)
Reactome MAPK3 (ERK1) activation
MAPK1 (ERK2) activation
WikiPathways SIDS Susceptibility Pathways
Senescence and Autophagy in Cancer
IL-6 signaling pathway
Differentiation Pathway
Interleukin-6 signaling
Ref 524991ClinicalTrials.gov (NCT02287922) A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health.
Ref 543089(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8363).
Ref 533248The preclinical pharmacology of the high affinity anti-IL-6R Nanobody? ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.